Intrinsic value of Teligent - TLGT

Previous Close

$6.15

  Intrinsic Value

$4.66

stock screener

  Rating & Target

sell

-24%

  Value-price divergence*

0%

Previous close

$6.15

 
Intrinsic value

$4.66

 
Up/down potential

-24%

 
Rating

sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of TLGT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  52.27
  25.00
  23.00
  21.20
  19.58
  18.12
  16.81
  15.63
  14.57
  13.61
  12.75
  11.97
  11.28
  10.65
  10.08
  9.58
  9.12
  8.71
  8.34
  8.00
  7.70
  7.43
  7.19
  6.97
  6.77
  6.60
  6.44
  6.29
  6.16
  6.05
  5.94
Revenue, $m
  67
  84
  103
  125
  149
  176
  206
  238
  273
  310
  350
  391
  436
  482
  531
  581
  634
  690
  747
  807
  869
  933
  1,001
  1,070
  1,143
  1,218
  1,297
  1,378
  1,463
  1,552
  1,644
Variable operating expenses, $m
 
  62
  77
  93
  111
  132
  154
  178
  204
  231
  261
  292
  325
  360
  396
  434
  473
  514
  557
  602
  648
  696
  746
  798
  853
  909
  967
  1,028
  1,091
  1,157
  1,226
Fixed operating expenses, $m
 
  14
  15
  15
  15
  16
  16
  17
  17
  17
  18
  18
  19
  19
  20
  20
  21
  21
  22
  22
  23
  24
  24
  25
  25
  26
  27
  27
  28
  29
  29
Total operating expenses, $m
  64
  76
  92
  108
  126
  148
  170
  195
  221
  248
  279
  310
  344
  379
  416
  454
  494
  535
  579
  624
  671
  720
  770
  823
  878
  935
  994
  1,055
  1,119
  1,186
  1,255
Operating income, $m
  3
  7
  11
  17
  22
  29
  36
  44
  52
  61
  71
  81
  92
  103
  115
  127
  140
  154
  168
  183
  198
  214
  230
  247
  265
  283
  303
  323
  344
  365
  388
EBITDA, $m
  7
  12
  18
  24
  31
  39
  48
  58
  69
  80
  92
  104
  118
  132
  147
  162
  178
  195
  213
  231
  250
  269
  290
  311
  333
  356
  380
  405
  431
  458
  486
Interest expense (income), $m
  5
  5
  7
  8
  10
  12
  15
  18
  20
  23
  27
  30
  34
  38
  42
  46
  51
  55
  60
  65
  71
  76
  82
  88
  94
  100
  107
  114
  121
  129
  136
Earnings before tax, $m
  -12
  2
  5
  8
  12
  16
  21
  26
  32
  38
  44
  51
  58
  65
  73
  81
  90
  98
  108
  117
  127
  137
  148
  159
  171
  183
  196
  209
  223
  237
  252
Tax expense, $m
  0
  0
  1
  2
  3
  4
  6
  7
  9
  10
  12
  14
  16
  18
  20
  22
  24
  27
  29
  32
  34
  37
  40
  43
  46
  49
  53
  56
  60
  64
  68
Net income, $m
  -12
  1
  3
  6
  9
  12
  15
  19
  23
  28
  32
  37
  42
  48
  53
  59
  65
  72
  79
  86
  93
  100
  108
  116
  125
  134
  143
  152
  162
  173
  184

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  66
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  183
  192
  236
  286
  342
  404
  472
  546
  626
  711
  802
  898
  999
  1,105
  1,217
  1,333
  1,455
  1,582
  1,713
  1,850
  1,993
  2,141
  2,295
  2,455
  2,621
  2,794
  2,974
  3,161
  3,356
  3,559
  3,770
Adjusted assets (=assets-cash), $m
  117
  192
  236
  286
  342
  404
  472
  546
  626
  711
  802
  898
  999
  1,105
  1,217
  1,333
  1,455
  1,582
  1,713
  1,850
  1,993
  2,141
  2,295
  2,455
  2,621
  2,794
  2,974
  3,161
  3,356
  3,559
  3,770
Revenue / Adjusted assets
  0.573
  0.438
  0.436
  0.437
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.435
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
Average production assets, $m
  70
  88
  108
  130
  156
  184
  215
  249
  285
  324
  365
  409
  455
  504
  554
  607
  663
  721
  781
  843
  908
  976
  1,046
  1,119
  1,194
  1,273
  1,355
  1,440
  1,529
  1,621
  1,718
Working capital, $m
  88
  27
  34
  41
  49
  58
  68
  78
  90
  102
  115
  128
  143
  158
  174
  191
  208
  226
  245
  265
  285
  306
  328
  351
  375
  400
  425
  452
  480
  509
  539
Total debt, $m
  111
  143
  179
  220
  266
  317
  372
  433
  498
  568
  642
  721
  804
  891
  983
  1,078
  1,178
  1,282
  1,390
  1,502
  1,619
  1,741
  1,867
  1,998
  2,134
  2,276
  2,424
  2,577
  2,737
  2,903
  3,077
Total liabilities, $m
  127
  158
  194
  235
  281
  332
  387
  448
  513
  583
  657
  736
  819
  906
  998
  1,093
  1,193
  1,297
  1,405
  1,517
  1,634
  1,756
  1,882
  2,013
  2,149
  2,291
  2,439
  2,592
  2,752
  2,918
  3,092
Total equity, $m
  57
  35
  43
  52
  62
  73
  85
  98
  113
  128
  144
  162
  180
  199
  219
  240
  262
  285
  308
  333
  359
  385
  413
  442
  472
  503
  535
  569
  604
  641
  679
Total liabilities and equity, $m
  184
  193
  237
  287
  343
  405
  472
  546
  626
  711
  801
  898
  999
  1,105
  1,217
  1,333
  1,455
  1,582
  1,713
  1,850
  1,993
  2,141
  2,295
  2,455
  2,621
  2,794
  2,974
  3,161
  3,356
  3,559
  3,771
Debt-to-equity ratio
  1.947
  4.120
  4.200
  4.260
  4.310
  4.350
  4.380
  4.400
  4.420
  4.440
  4.450
  4.460
  4.470
  4.480
  4.490
  4.490
  4.500
  4.500
  4.510
  4.510
  4.510
  4.520
  4.520
  4.520
  4.520
  4.530
  4.530
  4.530
  4.530
  4.530
  4.530
Adjusted equity ratio
  -0.077
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -12
  1
  3
  6
  9
  12
  15
  19
  23
  28
  32
  37
  42
  48
  53
  59
  65
  72
  79
  86
  93
  100
  108
  116
  125
  134
  143
  152
  162
  173
  184
Depreciation, amort., depletion, $m
  4
  5
  6
  7
  9
  11
  12
  14
  16
  19
  21
  23
  26
  29
  32
  35
  38
  41
  45
  48
  52
  56
  60
  64
  68
  73
  77
  82
  87
  93
  98
Funds from operations, $m
  -4
  6
  10
  13
  18
  23
  28
  33
  40
  46
  53
  60
  68
  76
  85
  94
  103
  113
  123
  134
  145
  156
  168
  180
  193
  206
  220
  235
  250
  266
  282
Change in working capital, $m
  -5
  5
  6
  7
  8
  9
  10
  11
  11
  12
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  30
Cash from operations, $m
  1
  1
  3
  6
  10
  14
  18
  23
  28
  34
  40
  47
  54
  61
  69
  77
  86
  95
  104
  114
  124
  135
  146
  157
  169
  182
  195
  208
  222
  237
  252
Maintenance CAPEX, $m
  0
  -4
  -5
  -6
  -7
  -9
  -11
  -12
  -14
  -16
  -19
  -21
  -23
  -26
  -29
  -32
  -35
  -38
  -41
  -45
  -48
  -52
  -56
  -60
  -64
  -68
  -73
  -77
  -82
  -87
  -93
New CAPEX, $m
  -19
  -18
  -20
  -23
  -26
  -28
  -31
  -34
  -36
  -39
  -41
  -44
  -46
  -48
  -51
  -53
  -55
  -58
  -60
  -62
  -65
  -67
  -70
  -73
  -76
  -79
  -82
  -85
  -89
  -92
  -96
Cash from investing activities, $m
  -22
  -22
  -25
  -29
  -33
  -37
  -42
  -46
  -50
  -55
  -60
  -65
  -69
  -74
  -80
  -85
  -90
  -96
  -101
  -107
  -113
  -119
  -126
  -133
  -140
  -147
  -155
  -162
  -171
  -179
  -189
Free cash flow, $m
  -21
  -21
  -22
  -23
  -23
  -24
  -23
  -23
  -22
  -21
  -20
  -18
  -16
  -13
  -10
  -7
  -4
  -1
  3
  7
  11
  16
  20
  25
  30
  35
  40
  45
  51
  57
  63
Issuance/(repayment) of debt, $m
  0
  32
  36
  41
  46
  51
  56
  61
  65
  70
  74
  79
  83
  87
  91
  96
  100
  104
  108
  112
  117
  121
  126
  131
  136
  142
  147
  153
  160
  166
  173
Issuance/(repurchase) of shares, $m
  0
  6
  4
  3
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  0
  38
  40
  44
  47
  51
  56
  61
  65
  70
  74
  79
  83
  87
  91
  96
  100
  104
  108
  112
  117
  121
  126
  131
  136
  142
  147
  153
  160
  166
  173
Total cash flow (excl. dividends), $m
  -21
  17
  19
  21
  24
  27
  32
  38
  43
  49
  55
  61
  67
  74
  81
  88
  96
  103
  111
  119
  128
  137
  146
  156
  166
  176
  187
  199
  211
  223
  236
Retained Cash Flow (-), $m
  10
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -32
  -34
  -35
  -37
  -38
Prev. year cash balance distribution, $m
 
  29
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  39
  11
  12
  14
  16
  20
  24
  29
  33
  38
  44
  49
  55
  61
  67
  74
  80
  87
  95
  102
  110
  119
  127
  136
  145
  155
  165
  176
  187
  198
Discount rate, %
 
  6.70
  7.04
  7.39
  7.76
  8.14
  8.55
  8.98
  9.43
  9.90
  10.39
  10.91
  11.46
  12.03
  12.63
  13.27
  13.93
  14.63
  15.36
  16.12
  16.93
  17.78
  18.67
  19.60
  20.58
  21.61
  22.69
  23.82
  25.01
  26.26
  27.58
PV of cash for distribution, $m
 
  36
  10
  10
  10
  11
  12
  13
  14
  14
  14
  14
  13
  13
  12
  10
  9
  8
  7
  6
  4
  4
  3
  2
  2
  1
  1
  1
  0
  0
  0
Current shareholders' claim on cash, %
  100
  96.5
  94.2
  93.0
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6
  92.6

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical and branded generic injectable pharmaceutical products in the United States and Canada. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter (OTC) and cosmetic markets. Its products are used in various applications that range from cosmetics to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, the company offers pharmaceutical contract services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices; and contract development services that include development of topical formulations. It has a license agreement with Novavax, Inc. to utilize the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological OTC and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

FINANCIAL RATIOS  of  Teligent (TLGT)

Valuation Ratios
P/E Ratio -27.2
Price to Sales 4.9
Price to Book 5.7
Price to Tangible Book
Price to Cash Flow 326.9
Price to Free Cash Flow -18.2
Growth Rates
Sales Growth Rate 52.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 216.7%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 194.7%
Total Debt to Equity 194.7%
Interest Coverage -1
Management Effectiveness
Return On Assets -3.8%
Ret/ On Assets - 3 Yr. Avg. 2.6%
Return On Total Capital -7.1%
Ret/ On T. Cap. - 3 Yr. Avg. 1.3%
Return On Equity -19.4%
Return On Equity - 3 Yr. Avg. 5.2%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 52.2%
Gross Margin - 3 Yr. Avg. 50%
EBITDA Margin -4.5%
EBITDA Margin - 3 Yr. Avg. 14.8%
Operating Margin 4.5%
Oper. Margin - 3 Yr. Avg. 3.1%
Pre-Tax Margin -17.9%
Pre-Tax Margin - 3 Yr. Avg. 4.2%
Net Profit Margin -17.9%
Net Profit Margin - 3 Yr. Avg. 4.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

TLGT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the TLGT stock intrinsic value calculation we used $67 million for the last fiscal year's total revenue generated by Teligent. The default revenue input number comes from 2016 income statement of Teligent. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our TLGT stock valuation model: a) initial revenue growth rate of 25% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.7%, whose default value for TLGT is calculated based on our internal credit rating of Teligent, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Teligent.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of TLGT stock the variable cost ratio is equal to 74.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $14 million in the base year in the intrinsic value calculation for TLGT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.7% for Teligent.

Corporate tax rate of 27% is the nominal tax rate for Teligent. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the TLGT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for TLGT are equal to 104.5%.

Life of production assets of 17.5 years is the average useful life of capital assets used in Teligent operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for TLGT is equal to 32.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $57 million for Teligent - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 50.714 million for Teligent is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Teligent at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
IPXL Impax Laborato 18.45 5.47  str.sell
PFE Pfizer 32.67 28.58  hold
AKRX Akorn 31.98 24.23  sell
RDY Dr. Reddy' 30.75 20.09  str.sell
NVS Novartis ADR 82.76 35.73  str.sell
TARO Taro Pharmaceu 101.89 268.30  str.buy
AMPH Amphastar Phar 15.22 1.79  str.sell

COMPANY NEWS

▶ Teligent reports 2Q loss   [Aug-08-17 04:48PM  Associated Press]
▶ ETFs with exposure to Teligent, Inc. : July 11, 2017   [Jul-11-17 03:06PM  Capital Cube]
▶ 3 Healthcare Stocks for Ambitious Investors   [Jun-15-17 04:23PM  Motley Fool]
▶ ETFs with exposure to Teligent, Inc. : June 14, 2017   [Jun-14-17 01:52PM  Capital Cube]
▶ ETFs with exposure to Teligent, Inc. : May 31, 2017   [May-31-17 12:49PM  Capital Cube]
▶ ETFs with exposure to Teligent, Inc. : May 16, 2017   [May-16-17 01:01PM  Capital Cube]
▶ ETFs with exposure to Teligent, Inc. : May 3, 2017   [May-03-17 04:23PM  Capital Cube]
▶ Teligent tops 1Q profit forecasts   [May-02-17 07:11PM  Associated Press]
▶ The 3 Best Pharmaceutical Stocks to Buy in 2017   [Apr-29-17 03:31PM  Motley Fool]
▶ Teligent, Inc. Appoints Martin Wilson To General Counsel   [Apr-25-17 08:00AM  PR Newswire]
▶ ETFs with exposure to Teligent, Inc. : April 20, 2017   [Apr-20-17 02:32PM  Capital Cube]
▶ Biotech Movers Trading Positive Ahead of Market's Open   [Apr-11-17 09:30AM  TheStreet.com]
▶ 3 Stocks That Could Make You Rich   [Mar-26-17 07:22AM  Motley Fool]
▶ 3 Stocks That Could Make You Rich   [07:22AM  at Motley Fool]
▶ Teligent reports 4Q loss   [Mar-07-17 04:58PM  Associated Press]
▶ 3 Little-Known Pharmaceutical Companies to Put on Your Radar   [Jan-12-17 03:54PM  at Motley Fool]
▶ These 3 Stocks Are Up Over 500% Over the Last 5 Years   [Dec-19-16 08:50AM  at Motley Fool]
▶ Should You Buy Teligent Inc (TLGT)?   [Dec-15-16 10:09AM  at Insider Monkey]
▶ 3 Top Stocks Under $10   [Sep-30-16 11:10AM  at Motley Fool]
Stock chart of TLGT Financial statements of TLGT
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.